Article

Retisert implant effective for uveitis, promising for diabetic macular edema and vein occlusion

The Retisert implant (Bausch & Lomb), a nonbiogradable device containing fluocinolone acetonide, is approved for the treatment of uveitis and seems promising in diabetic macular edema (DME) and vein occlusion, according to Glenn Jaffe, MD. He reported his experience with the implant on Friday during retina subspecialty day at the American Academy of Ophthalmology annual meeting.

Chicago-The Retisert implant (Bausch & Lomb), a nonbiogradable device containing fluocinolone acetonide, is approved for the treatment of uveitis and seems promising in diabetic macular edema (DME) and vein occlusion, according to Glenn Jaffe, MD. He reported his experience with the implant on Friday during retina subspecialty day at the American Academy of Ophthalmology annual meeting.

“The advantages of this therapeutic approach are linear drug delivery, the drug is contained within a nontoxic device, and the device is suitable for sustained delivery of the drug for years,” he said. In this case, the expected duration of drug release is 2.5 to 3 years.

Dr. Jaffe is professor of ophthalmology, Duke University, Durham, NC. He evaluated the implant to treat uveitis during an individual investigator (IND) trial in 36 eyes of 32 patients who had severe noninfectious uveitis with posterior segment involvement that was refractory to standard therapy. The average follow-up was 2 years.

“The implant had potent anti-inflammatory effects. Whereas these patients had 2.5 recurrences of uveitis per eye annually, postoperatively there were no recurrences at 2 years and two recurrences at 29 months to 3 years,” Dr. Jaffe reported. Most patients had stabilized or improved visual acuity. The side effects are cataract development and increased IOP. Larger clinical trials of the Retisert implant for uveitis showed results that were similar to Dr. Jaffe’s trial.

The Retisert implant is also being tested to treat DME and as salvage therapy in patients with vein occlusion and appears promising in both cases.

Dr. Jaffe emphasized that tight wound closure is imperative in this procedure to avoid infection and wound leaks and that the patients must be provided with realistic expectations prior to surgery and the possibility of the development of cataract.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.